InsiderPulse
← 10-K / 10-Q
10-QVYNE

VYNE Therapeutics Inc.

Filed 2026-05-15Period ending 2026-03-31
EDGAR ↗All periods →

Income Statement

Line Item2026-03-31Q/QY/Y
Revenue$86K-57.4%
R&D Expense$817K-86.7%
SG&A Expense$3.1M-5.8%
Operating Income-$3.8M+58.5%
Pre-tax Income-$3.6M+58.3%
Income Tax$0
Net Income-$3.6M+58.4%
EPS (Basic)-$0.08+60.0%
EPS (Diluted)-$0.08+60.0%

Balance Sheet

Line Item2026-03-31Q/QY/Y
Cash & Equivalents$24.6M+2.5%-12.7%
Short-term Investments$297K-94.0%-98.7%
Current Assets$25.8M-14.1%-53.0%
Total Assets$25.9M-14.2%-54.1%
Current Liabilities$1.2M-48.4%-89.9%
Long-term Debt$0
Total Liabilities$1.2M-48.4%-89.9%
Stockholders' Equity$24.6M-11.3%-44.2%

Cash Flow

Line Item2026-03-31Q/QY/Y
Operating Cash Flow-$4.1M+64.4%
Investing Cash Flow$4.7M-76.3%
Financing Cash Flow-$15K+82.8%